LMR Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

LMR Partners’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	-$500K	–	1320
2021 Q1	$500K	Buy	+1	New	+$765K	0.01%	627

Other funds holding TNXP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LMR Partners's TNXP Position: Q2 2021 in Review

LMR Partners sold out of Tonix Pharmaceuticals (TNXP) in Q2 2021, closing a stake of 1 share — an estimated $500K sold.

LMR Partners first reported a position in TNXP in Q1 2021 and held it in 1 quarter. The position peaked at $500K in Q1 2021. 15 funds tracked by Wall St. Rank hold TNXP as of Q2 2021.

LMR Partners reported no remaining Tonix Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
LMR Partners sold 1 Tonix Pharmaceuticals share in Q2 2021, an estimated $500K.
LMR Partners first reported a position in Tonix Pharmaceuticals in Q1 2021 and held it in 1 quarter.
LMR Partners's Tonix Pharmaceuticals position peaked at $500K in Q1 2021.
15 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2021.

Based on LMR Partners's 13F filing for Q2 2021, filed 16 Aug 2021.